Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | QDPR | P09417 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27840522 | 0.85 | NISCH (0.37) | HRH4SLC18A3SIGMAR1HTR2CDPP7 | |
| SCHEMBL28247554 | 0.85 | SLC18A3 (0.39) | HRH4SLC18A3SIGMAR1HTR2CHTR3A | |
| SCHEMBL3764762 | 0.82 | — | — | |
| SCHEMBL7499316 | 0.81 | — | — | |
| SCHEMBL149012 | 0.79 | — | — | |
| SCHEMBL7501843 | 0.74 | CYP2D6 (0.38) | HTR2CHTR3A | |
| SCHEMBL18763492 | 0.74 | HRH4 (0.36) | HRH4SLC18A3SIGMAR1HTR3A | |
| SCHEMBL25391815 | 0.73 | — | — | |
| SCHEMBL102091 | 0.73 | — | — | |
| SCHEMBL102511 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253010-B2 | C-glycoside derivative | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2019-04-09 | — | — | US | disclosed |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-13 | — | — | US | disclosed |
| US-9562029-B2 | C-glycoside derivatives | Xuanzhu Pharma Co., Ltd. (CN) | 2017-02-07 | — | — | US | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| EP-2725031-B1 | C-GLYCOSIDE DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2016-08-03 | — | — | EP | disclosed |
| US-20140243288-A1 | FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-28 | — | — | US | disclosed |
| EP-2762480-A1 | OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-05-08 | — | — | US | disclosed |
| EP-2725031-A1 | C-GLYCOSIDE DERIVATIVES | Xuanzhu Pharma Co., Ltd. (CN) | 2014-04-30 | — | — | EP | disclosed |
| US-7816398-B2 | Fatty alcohol drug conjugates | LUITPOLD PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-4345071-A | AZIDOALKYL-HETEROCYCLIC AMIDINE INTERMEDIATES | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1982-08-17 | — | — | US | disclosed |
| US-4259333-A | ANTIBIOTICS, BACTERICIDES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1981-03-31 | — | — | US | disclosed |
| US-4246262-A | ANTIBIOTICS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1981-01-20 | — | — | US | disclosed |
| US-4229443-A | Derivatives of penicillanic acid | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128331-A1 | C-GLYCOSIDE DERIVATIVES | RDX, C3AR1, C1R | HRH4 1145/4885SLC18A3 3239/4885SIGMAR1 1843/4885 |
| US-20140243288-A1 | FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS | OXA1L, O60361, OXER1 | HRH4 226/4885SLC18A3 4819/4885SIGMAR1 1824/4885 |
| US-10253010-B2 | C-glycoside derivative | RDX, C1R, C3AR1 | HRH4 1114/4885SLC18A3 3261/4885SIGMAR1 1912/4885 |
| US-20170101388-A1 | C-GLYCOSIDE DERIVATIVE | RDX, C1R, C3AR1 | HRH4 1114/4885SLC18A3 3261/4885SIGMAR1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.